Hypertension is a common and independent risk factor for cardiovascular mortality worldwide, and therefore, the importance of effective treatment cannot be overemphasized. 1, 2 It has been shown in many different randomized controlled trials that blood pressure (BP) reduction is associated with reduced cardiovascular morbidity and mortality. 3, 4 Furthermore, a meta-analysis of 61 prospective observational studies covering 1 million adults and 12.7 million person-years at risk has substantiated that for every 2-mm Hg difference in mean systolic blood pressure (SBP), there are a 7% difference in the risk of ischemic heart disease mortality and a 10% difference in the risk of cerebrovascular accident. 5 Reducing blood pressure to target levels is therefore a major priority in preventing clinical events in hypertension, and typically, this requires more than 1 medication in the majority of patients. For example, in the large Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack trial, less than 30% of the subjects achieved BP goal on monotherapy. 6 Randomized controlled trials (RCTs) in hypertension as early as the 1950s showed that patients with malignant hypertension were markedly transformed by the introduction of antihypertensive therapy. 7 Over the following decades (during the 1970s, 1980s, and early 1990s), trials of severe and moderate hypertension confirmed the cardioprotective, renoprotective, and neuroprotective benefits of lowering BP, with a series of placebo-controlled trials of milder levels of hypertension also taking place. 7 By the end of 1980s, the results of a number of these placebo-controlled trials in hypertension showed in meta-analysis that a reduction in SBP of 10-12 mm Hg and diastolic BP (DBP) reduction of 6-7 mm Hg reduced the incidence of cerebrovascular accident by about 40%, 4 which was comparable with the risk reduction reported from prospective observational studies. 8 However, the risk of nonfatal myocardial infarction and coronary heart disease death was reduced by about 14%, which is less than what was expected from prospective observational data. 4, 5 Following these placebo-controlled trials and the resultant metaanalyses, a series of trials set out to compare the benefits of contemporary drugs over standard therapy. In 2000, the Blood Pressure Lowering Treatment Trialists Collaboration published a meta-analysis of these trials that included data from approximately 75,000 patients. This demonstrated that angiotensin receptor blockers were effective in reducing total cardiovascular events, that angiotensin-converting enzyme (ACE) inhibitors and diuretic plus β-blocker-based regimens are more effective than calcium channel blockers in preventing heart failure, and that calcium channel blockers may be more effective in preventing stroke. 9 Results from various RCTs showed that most patients with hypertension require at least 2 BP-lowering agents if recommended targets are to be reached. [10] [11] [12] [13] [14] [15] [16] Consequently, there has been a lot of emphasis by the various guidelines on the use of combinations of 2 or 3 agents on the management of hypertension. [17] [18] [19] [20] [21] Guidelines differ regarding which combination of 2 BP-lowering agents they recommend, and none has been able to recommend with certainty optimal combinations for black populations. [19] [20] [21] [22] [23] This is because there are no large RCTs that have compared the efficacy of contemporary combination therapies among any black populations 24 despite the high burden of hypertension and its complications in this group.
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Rationale for the study
Although it might be argued that findings in African Americans can be extrapolated to black Africans because they have the same ancestral origin, the differences in selection in previous generations, ethnic admixture, and differences in lifestyle suggest that such an extrapolation may be inappropriate. [28] [29] [30] In addition, among African American patients with hypertension, no large RCTs trials have evaluated optimal combinations of antihypertensive medications.
Hypothesis
Previous studies in black Africans showed calcium channel blockers and diuretics to be more efficacious as monotherapy when compared with ACE inhibitors. 31, 32 Based on these, we aim to test the hypothesis that therapy with a combination of amlodipine plus hydrochlorothiazide is more efficacious than the combinations of perindopril plus amlodipine and perindopril plus hydrochlorothiazide in reducing mean 24-hour ambulatory systolic blood pressure (ASBP) levels in black Africans.
Objectives

Primary objectives
The primary objective of the CREOLE study is to determine which of the 3 "two-drug" antihypertensive combinations of amlodipine plus perindopril versus amlodipine plus hydrochlorothiazide versus perindopril plus hydrochlorothiazide is most effective in reducing 24-hour ASBP in black African patients with hypertension.
Secondary objectives
The secondary objectives of the study are: 2. To determine which of the 3 combinations of 2 antihypertensive agents is most effective in increasing the proportion of patients who achieve BP control (BP control is defined as SBP b 140 mm Hg and DBP b 90 mm Hg) and the proportion of patients classified as "responders" (responders are defined as those with a reduction of SBP N 20 mm Hg and DBP N 10 mm Hg during the trial). 3. To determine the effect of these 3 combinations on: a) Micro-and macroalbuminuria b) Fasting blood glucose c) Fasting lipid profile d) Serum sodium, potassium, urea, creatinine, and estimated glomerular filtration rate e) Adverse events causing permanent discontinuation of therapy.
Study design
The CREOLE trial is a randomized single-blind trial comparing the efficacy of amlodipine plus hydrochlorothiazide with a combination of amlodipine plus perindopril and a combination of perindopril plus hydrochlorothiazide ( Figure 1 ).
Although the study is strictly classified as single-blinded because the commercial products to be used do not match each other, measures will be taken to mask the identity of dispensed medications to minimize bias. Such measures include repackaging the products into identical blister packs with identical labels such that patients, pharmacists administering the medications, and physicians assessing the outcomes are not aware of the group assignments. In addition, physicians and investigators do not have any access to the medications because during follow-up visits, the patient reports first to the site pharmacist who collects any remaining packs before sending the patient to the physician. And after follow-up review by the physicians, the patient goes to the study pharmacist to collect fresh medications and does not return to the physician. Furthermore, the pharmacist educates the patient not to reveal the color or shapes of the tablets he or she is taking. And lastly, during site initiation visits and training, investigators were trained never to ask of the shape or color of patients' medications because this is completely blinded to them.
Allocation to study groups is performed using randomization in a 1:1:1 allocation ratio, with stratification by age (less than 55 years or 55 years and above), and blocked by site. A randomization list is drawn up centrally for each site and includes enrolment numbers randomly allocated to 1 of the 3 trial combinations of amlodipine plus perindopril or amlodipine plus hydrochlorothiazide or perindopril plus hydrochlorothiazide. Enrolled patients take their allocated enrolment numbers to the pharmacy where the corresponding study medications are dispensed to them in medication blister packs labeled with unique patient identification numbers consisting of the center and randomization numbers.
The label contains dosing instructions and temperature storage requirements. All labeling is in English. After the 2-month clinic visit, patients receive a higher dose of the same medication they were randomized to and instructed to complete the treatment.
Patients commence treatment at a starting dose of amlodipine/hydrochlorothiazide 5/12.5 mg, amlodipine/perindopril 5/4 mg, or perindopril/hydrochlorothiazide 4/12.5 mg. These doses will be increased at the 2-month visit to amlodipine/hydrochlorothiazide 10/25 mg, amlodipine/perindopril 10/8 mg, or perindopril/hydrochlorothiazide 8/25 mg unless patients cannot tolerate higher doses as judged by the physician or have an SBP of less than 100 mm Hg.
If, after 4 months of treatment, clinic SBP is greater than 160 mm Hg or DBP is greater than 100 mm Hg, atenolol 50 mg once daily will be added to the trial therapy unless contraindicated, in which case an alternative agent that is not a thiazide diuretic, ACE inhibitor, or calcium channel blocker such as 12.5 mg of spironolactone or 2 mg of doxazosin will be added at the investigator's discretion. Although the intention-to-treat principle will be maintained, there will be sensitivity analyses excluding BP values from this group of patients on nontrial agents by carrying forward their 4-month BP data to 6 months. All patients will be randomized and followed up for 6 months. Last patient follow-up visit will occur 18 months after first patient randomized ( Figure 2 ).
Study population
The enrolled patients are those referred to primary and secondary care in the study sites for the management of primary hypertension ( Figure 3) .
Inclusion criteria
Eligible patients will be aged 30-79 years with a sitting SBP ≥140 mm Hg and b160 mm Hg on antihypertensive monotherapy, or sitting SBP ≥ 150 mm Hg and b180 mm Hg on no antihypertensive treatment. 
Exclusion criteria
The following patients will be excluded from the study: 
Primary end point
The primary outcome measure is change in ASBP from baseline to 6 months. This will be calculated as the difference between the mean ASBP at randomization and that at the end of follow-up. ABPM will be used because it is a better reflection of true overall BP and therefore a stronger predictor of adverse CV events than routine clinic readings. 30, 31 Ambulatory blood pressure will be performed with MEDITECH ABPM monitors (ABPM-05 model). Patients will wear the ABPM device for a minimum of 24 hours with automatic readings every 30 minutes both in the daytime and at night. 30, 31 Daytime will be defined as 9:00 AM through 9:00 PM and nighttime as midnight through 6:00 AM.
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Small, medium, or large blood pressure cuffs will be used as appropriate on the nondominant arm.
Secondary end point
The secondary end points include:
1. Change in ADBP from baseline to 6 months 2. Change in clinic BP from baseline to 2, 4, and 6 months 3. Change in daytime and nighttime BP measured using ABPM from baseline to 6 months 4. BP variability also measured using ABPM 5. Proportion of patients who achieve BP control at 2, 4, and 6 months (with BP control defined as less than140 mm Hg SBP and less than 90 mm Hg DBP)
6. Proportion of "responders" (responders defined as clinic BP reduction greater than 20 mm Hg SBP and greater than 10 mm Hg DBP) at 2, 4, and 6 months 7. Change in micro-and macroalbuminuria measured using spot urine at baseline and 6 months 8. Changes in fasting blood glucose concentration, fasting lipid profile, serum sodium, potassium urea, creatinine, and estimated glomerular filtration rate from baseline to 6 months 9. Adverse events causing permanent discontinuation of trial therapy.
Statistical considerations and study size
Power of the study
The sample size calculation is based on detecting a 3.0-mm Hg difference in the 24-hour mean ASBP assuming a standard deviation in 24-hour ASBP of 9 mm Hg. By recruiting a total of 702 participants (234 participants per group), in order to achieve a total of 210 evaluable participants per group (assuming a 10% dropout rate). This will provide the trial with a power of 84% at a significance level of 5%.
Statistical analysis
Mean differences among the 3 randomized groups will be analyzed using the analysis of variance test, and if required, the Turkey post hoc test, and differences in proportions will be analyzed using the χ 2 test
or Fisher exact test, as appropriate. These analyses will include comparison of absolute 24-hour ASBP values, 24-hour BP variability, mean nighttime and daytime ambulatory BP, rates of BP control and BP response, clinic systolic and diastolic BPs, and other variables. Analyses at 2 and 6 months will also be conducted using the mixed model repeated measures. A sensitivity analysis will be conducted excluding BP values from those on nontrial agents at 6 months with a carrying forward of 4-month BPs. Multiple linear regression analysis and logistic regression analysis will be conducted to determine variables associated with continuous or binary outcomes, respectively. Analysis will be further stratified by presence or absence of diabetes mellitus, and age less than b55 years versus 55 years and above. The Stata (College Station, TX) statistical software will be used for data analysis.
Analysis of missing outcome data
The analysis will be conducted according to the intention-to-treat principle, meaning that participants will be analyzed in the groups to which they will have been randomized regardless of compliance with the protocol. Patients who have discontinued study drug will be invited to attend scheduled clinic visits. If the subject does not attend study visits, follow-up will be attempted by telephone or e-mail to obtain information regarding study outcomes and adverse events. Imputation of some missing data will be carried out subsequently for sensitivity analyses of ABPM, height, weight, and laboratory values using the multiple imputation technique.
Ethical principles
The study is conducted in accordance with the guidelines laid down by the International Conference on Harmonisation for Good Clinical Practice. All investigators obtained ethical approval from their local institutional review boards which are affiliates of their national review boards. Eligible patients are approached regarding potential participation in the study, and the study purpose, procedures, risks, and potential benefits are explained by the study coordinator and/or principal investigators. Potential patients are given the opportunity to ask questions. Patients who voluntarily agree to participate in the study are asked to document their informed consent.
Management of the study
Study personnel at the participating sites are responsible for completing case report forms through accessing a computerized program (Electronic Clinical Data Management System) via the Internet and entering the required trial information for electronic submission to the server located at the Data Management and Monitoring Centre at University of Cape Town. This includes all relevant BP variables uploaded directly from the MEDITECH machines into the Electronic Clinical Data Management System database.
The University of Abuja serves as the Project Coordinating Centre. Both the Universities of Abuja and Cape Town have access to all the study data. Individual sites will have access to their own center's data and are provided site-specific data summaries periodically by the Data Management and Monitoring Centre in Cape Town. Source documentation supporting the trial information are stored at the investigator site and made available for trial-related monitoring, audits, Institutional Review Board (IRB)/Institutional Ethics Committee (IEC) review, and regulatory inspections when required. The investigator retains all study record files in accordance with applicable regulatory requirements. The data management plan outlines the procedures and guidelines to ensure that data quality is adhered to.
Patient information will be stored in a high-security computer system and kept strictly confidential. Subject confidentiality will further be ensured by using a subject identification code number to correspond to treatment data on the computerized files. Only the Data Management and Monitoring Centre will be aware of the unblinded data until the trial is completed or a recommendation is made to terminate the trial.
A Trial Operations Committee consisting of members of the Abuja and Cape Town Project Coordinating Offices meets via telephone conference on a weekly basis to address the operational matters of the study and to implement the decisions of the Trial Steering Committee.
The Trial Steering Committee consists of the principal investigator, the co-principal investigators, the national coordinator for each country, the statistician, the study pharmacist, and the trial monitor. The principal investigator chairs this committee, and the Trial Steering Committee meets monthly.
An external and independent Data Safety and Monitoring Committee (DSMC) monitors the trial for safety and efficacy. The DSMC reviews the data for safety when all 2-month data, 4-month data, and 6-month data are ready and then as determined by the DSMC.
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Discussion
The CREOLE trial is the first randomized controlled trial to compare the efficacy of 3 frontline combination therapies in the treatment of hypertensive black patients living in sub-Saharan Africa. This study is timely because the most efficacious 2-drug combination in hypertensive black patients living in sub-Saharan Africa is still a matter of debate, as there are no large RCT data in this population group which have compared contemporary frontline combinations despite the high burden of hypertension and its complications in this group. [25] [26] [27] Although it could be argued that findings in African Americans can be extrapolated to black Africans because they have the same ancestral origin, the differences in selection in previous generations, ethnic admixture, and differences in lifestyle between these 2 populations suggest that such an extrapolation may be inappropriate. [28] [29] [30] Calcium channel blockers and diuretics have been found to be more efficacious as monotherapy in black Africans than whites when compared with ACE inhibitors. 33, 34 What is not known however is whether therapy with a combination of calcium channel blocker plus hydrochlorothiazide may be more efficacious than the combinations of calcium channel blocker plus ACE inhibitor or ACE inhibitor plus hydrochlorothiazide in reducing mean 24-hour ASBP levels in black Africans. The 3 combination therapies will be force-titrated to the highest doses after 2 months, which will allow for proper comparison among the 3 study arms. To ensure optimal BP control, if at the 4-month visit clinic SBP is greater than160 mm Hg and/or DBP is greater than 100 mm Hg, atenolol 50 mg once daily will be added to the trial therapy. Atenolol is chosen because of easy access to it at the various studies sites. However, if atenolol is contraindicated, an alternative agent that is not a thiazide diuretic, calcium channel blocker, or ACE inhibitor such as 12.5 mg of spironolactone or 2 mg of doxazosin will be added at the physicians' or investigators' discretion.
In conclusion, although current guidelines recommend the use of combination therapy as first-line treatment or early in the management of hypertensive patients, the best combination in blacks living in sub-Saharan Africa is still a matter of debate because there are no large RCTs comparing different combination therapies in this population. The CREOLE trial will therefore provide unique information as to the most efficacious 2-drug combination in black patients in sub-Saharan Africa and ultimately inform the development of clinical guidelines for the treatment of hypertension for this region. 35 
Study status
The first patient was randomized in June 2017. The total number of patients randomized as of the end of 2 October 2017 is 404 (Figures 4  and 5 ).
Summary
The CREOLE study when completed will be the first RCT to prospectively compare the efficacy of 3 frontline antihypertensive combination therapies in blacks residing in sub-Saharan Africa. The results of this trial will provide unique data for evidence-based treatment of hypertension in the subregion.
Disclosure
CREOLE study is registered with ClinicalTrials.gov (NCT02742467). The authors are solely responsible for the design and conduct of the study. They are also responsible for all the study analysis, the drafting and editing of manuscript, and its final content. The authors have no conflicts of interest. N. P. has however received speaker and advisory board honoraria from several companies producing BP-lowering agents.
Funding/Contributions/Acknowledgements
Although the medications were donated by ASPEN pharmaceutical (because it is the only pharmaceutical company in subSaharan Africa found to manufacture all the 3 classes of generic medications used in this study), they are not in any way involved in design, conduct, and analysis this study. Aspen is an approved manufacturer by the South African regulator, the Medicines Control Council, and has a license to manufacture. They are audited and checked regularly to ensure that they comply with Good Manufacturing Practices to have this license. The Medicines Control Council of South Africa is part of the Pharmaceutical Inspection Co-operation Scheme which is an international agreement between regulatory authorities to harmonize inspection procedures worldwide by developing common standards in the field of good manufacturing practice.
